Baird Financial Group Inc. Raises Holdings in Hims & Hers Health, Inc. $HIMS

Key Points

• Baird Financial Group increased its Hims & Hers Health stake by 384.6% in the second quarter, ending with 65,575 shares valued at approximately $2.27 million. Institutional investors collectively own 63.52% of the company.
• Hims & Hers faces negative legal and governance headlines, including a securities class-action lawsuit tied to alleged privacy, data-sharing, billing and disclosure issues. Insiders have also sold shares under pre-arranged Rule 10b5-1 plans.
• Analyst sentiment remains cautious, with an overall “Hold” rating and average price target of $32.43. Although quarterly revenue rose 38.2% year over year to $753.2 million, the company missed earnings expectations and reported a loss of $0.37 per share.

Baird Financial Group Inc. boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 384.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,575 shares of the company's stock after acquiring an additional 52,043 shares during the quarter. Baird Financial Group Inc.'s holdings in Hims & Hers Health were worth $2,273,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock worth $183,485,000 after purchasing an additional 608,950 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock valued at $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. State of Michigan Retirement System boosted its position in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock worth $48,549,000 after buying an additional 280,900 shares during the period. Norges Bank purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $62,153,000. Finally, Clear Street Group Inc. boosted its stake in shares of Hims & Hers Health by 23.6% in the fourth quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company's stock valued at $61,832,000 after purchasing an additional 363,893 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Bank of America Securities maintained its Hold rating on HIMS, indicating that the firm has not identified a sufficient catalyst to upgrade the stock despite the recent selloff. Bank of America Securities Sticks to Its Hold Rating
• Neutral Sentiment: COO Michael Chi and insider Soleil Boughton disclosed stock sales totaling roughly $572,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a direct bearish signal, although they add to the flow of insider-selling headlines.
• Negative Sentiment: Multiple law firms announced or promoted a federal securities class action against Hims & Hers and certain executives. The case covers investors who purchased shares from August 4, 2025, through July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. Kaplan Fox Class Action Notice
• Negative Sentiment: The litigation stems from an FTC federal complaint alleging serious business misconduct, including issues involving privacy and data-sharing practices, as well as deceptive privacy and billing practices. Plaintiffs allege that HIMS made material misstatements or omissions about these matters; the allegations have not been proven in court. Hims & Hers Securities Class Action

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 18,197 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91. Following the completion of the transaction, the chief financial officer directly owned 284,321 shares of the company's stock, valued at approximately $9,675,443.63. This trade represents a 6.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of Hims & Hers Health stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the transaction, the insider owned 313,964 shares in the company, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,291 shares of company stock worth $3,119,406 over the last ninety days. Insiders own 11.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Morgan Stanley increased their target price on Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research report on Tuesday, August 11th. Finally, Citigroup reduced their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $32.43.

Hims & Hers Health Stock Performance

HIMS stock opened at $27.92 on Friday. The company has a 50-day simple moving average of $30.19 and a 200 day simple moving average of $27.60. The company has a market capitalization of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm's quarterly revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 earnings per share. Sell-side analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.